Is the business good?
How good a business is PRCT?
PROCEPT BioRobotics Corporation earns −56% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−56%
Return on invested capital · cost of capital 9.0% · 65 points below what the capital costs: growth destroys value
- Operating margin
- −34%
Operating margin · Medical Devices median 11% · 12 months to Q1 2026
- Share count, year on year
- +2.9%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 24%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −619% |
| FY2021 | −157% |
| FY2022 | −108% |
| FY2023 | −80% |
| FY2024 | −43% |
| FY2025 | −34% |
Details›
- Gross margin12 months to Q1 2026
- 64%
- Operating margin12 months to Q1 2026
- −34%
- Net margin12 months to Q1 2026
- −32%
- Free cash flow margin
- −25%
- R&D as % of revenue
- 24%
- Revenue, trailing twelve months
- $322M
- Free cash flow, trailing twelve months
- −$81M
- Net income, trailing twelve months
- −$102M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −56%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.